Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases

World Journal of Gastroenterology

Volumn 9, Issue 2, 2003, Pages 359-363

  Yang, Li Qun ^a   Li, Shen Jing ^a   Cao, Yun Fei ^a   Man, Xiao Bo ^a   Yu, Wei Feng ^a   Wang, Hong Yang ^a   Wu, Meng Chao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450 3A4; ISOENZYME; MESSENGER RNA; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA PROBE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER HEMANGIOMA; LIVER PARENCHYMA; LIVER SURGERY; MALE; MARKER GENE; NORTHERN BLOTTING; OBSTRUCTIVE JAUNDICE; RNA EXTRACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

EID: 12244275665     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i2.359     Document Type: Article

References (51)

1. Kostrubsky VE, Ramachandran V, Venkataramanan R, Dorko K, Esplen JE, Zhang S, Sinclair JF, Wrighton SA, Strom SC. The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos 1999; 27: 887-894
2. Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyeresen R, Fujii-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF. The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 1991; 10: 1-10
3. Capdevila JH, Harris RC, Falck JR. Microsomal cytochrome P450 and eicosanoid metabolism. Cell Mol Life Sci 2002; 59: 780-789
4. Guengerich FP. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17
5. Raucy JL, Allen SW. Recent advances in P450 research. Pharmacogenomics J 2001; 1: 178-186
6. Zhu-Ge J, Yu YN, Qian YL, Li X. Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing. World J Gastroenterol 2002; 8: 888-892
7. Goodwin B, Redinbo MR, Kliewer SA. Regulation of cyp3a gene transcription by the pregnane × receptor. Annu Rev Pharmacol Toxicol 2002; 42: 1-23
8. Quattrochi LC, Guzelian PS. Cyp3A regulation: From pharmacology to nuclear receptors. Drug Metab Dispos 2001; 29: 615-622
9. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999; 369: 11-23
10. Nicholson TE, Renton KW. Modulation of cytochrome P450 by inflammation in astrocytes. Brain Res 1999; 827: 12-18
11. Dogra SC, Whitelaw ML, May BK. Transcriptional activation of cytochrome P450 genes by different classes of chemical inducers. Clin Exp Pharmacol Physiol 1998; 25: 1-9
12. Lieber CS. Ethanol metabolism, cirrhosis and alcoholism. Clin Chim Acta 1997; 257: 59-84
13. Paintaud G, Bechtel Y, Brientini MP, Miguet JP, Bechtel PR. Effects of liver diseases on drug metabolism. Therapie 1996; 51: 384-389
14. Brockmoller J, Roots J. Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 1994; 27: 216-248
15. Murray M. P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992; 23: 132-146
16. Lowry OH, Passonneau JV. Some recent refinements of quantitative histochemical analysis. Curr Probl Clin Biochem 1971; 3: 63-84
17. Omura T. Forty years of cytochrome P450. Biochem Biophys Res Commun 1999; 266: 690-698
18. Hover CG, Kulkarni AP. Lipoxygenase-mediated hydrogen peroxide-dependent N-demethylation of N,N-dimethylaniline and related compounds. Chem Biol Interact 2000; 124: 191-203
19. Chomczynski P, Sacch N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159
20. Goodwin B, Hodgson E, D'Costa DJ, Robertson GR, Liddle C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol 2002; 62: 359-365
21. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-172
22. Finnstrom N, Thorn M, Loof L, Rane A. Independent patterns of cytochrome P450 gene expression in liver and blood in patients with suspected liver disease. Eur J Clin Pharmacol 2001; 57: 403-409
23. Rodriguez-Antona C, Donato MT, Pareja E, Gomez-Lechon MJ, Castell JV. Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys 2001; 393: 308-315
24. Mitra AK, Patel J. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics 2001; 2: 401-415
25. De Wildt SN, Kearns GL, Leeder JS, Van Den Anker JN. Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet 1999; 37: 485-505
26. Hakkola J, Pelkonen O, Pasanen M, Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: Role in intrauterine toxicity. Crit Rev Toxicol 1998; 28: 35-72
27. Inaba T, Nebert DW, Burchell B, Watkins PB, Goldstein JA, Bertilsson L, Tucker GT. Pharmacogenetics in clinical pharmacology and toxicology. Can J Physiol Pharmacol 1995; 73: 331-338
28. El-Sankary W, Bombail V, Gibson GG, Plant N. Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos 2002; 30: 1029-1034
29. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30: 853-858
30. Shu Y, Cheng ZN, Liu ZQ, Wang LS, Zhu B, Huang SL, Ou-Yang DS, Zhou HH. Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. Acta Pharmacol Sin 2001; 22: 283-288
31. Tenneze L, Tarral E, Ducloux N, Funck-Brentano C. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: Comparison with the standard form and influence of the CYP2D6 polymorphism. Clin Pharmacol Ther 2002; 72: 112-122
32. Cai L, Yu SZ, Zhang ZF. Cytochrome P450 2E1 genetic polymorphism and gastric cancer in Changle, Fujian Province. World J Gastroenterol 2001; 7: 792-795
33. Zheng YX, Chan P, Pan ZF, Shi NN, Wang ZX, Pan J, Liang HM, Niu Y, Zhou XR, He FS. Polymorphism of metabolic genes and susceptibility to occupational chronic manganism. Biomarkers 2002; 7: 337-346
34. Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: Useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453-470
35. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209
36. Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 2001; 92: 147-163
37. Warren GW, Van Ess PJ, Watson AM, Mattson MP, Blouin RA. Cytochrome P450 and antioxidant activity in interleukin-6 knockout mice after induction of the acute-phase response. Interferon Cytokine Res 2001; 21: 821-826
38. De Smet K, Loyer P, Gilot D, Vercruysse A, Rogiers V, Guguen-Guillouzo C. Effects of epidermal growth factor on CYP inducibility by xenobiotics, DNA replication, and caspase activations in collagen I gel sandwich cultures of rat hepatocytes. Biochem Pharmacol 2001; 61: 1293-1303
39. Okamoto T, Okabe S. Minimal effect of cytokine-independent hepatitis induced by anti-Fas antibodies on hepatic cytochrome P450 gene expression in mice. Int J Mol Med 2000; 6: 459-462
40. Shoda T, Mitsumori K, Onodera H, Toyoda K, Uneyama C, Takada K, Hirose M. Liver tumor-promoting effect of beta-naphthoflavone, a strong CYP 1A1/2 inducer, and the relationship between CYP 1A1/2 induction and Cx32 decrease in its hepatocarcinogenesis in the rat. Toxicol Pathol 2000; 28: 540-547
41. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 1999; 24: 339-346
42. Morgan ET, Sewer MB, Iber H, Gonzalez FJ, Lee YH, Tukey RH, Okino S, Vu T, Chen YH, Sidhu JS, Omiecinski CJ. Physiological and pathophysiological regulation of cytochrome P450. Drug Metab Dispos 1998; 26: 1232-1240
43. Imaoka S, Funae Y. The physiological role of P450-derived arachidonic acid metabolites. Nippon Yakurigaku Zasshi 1998; 112: 23-31
44. Vuyk J. Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. Acta Anaesthesiol Belg 2001; 52: 445-451
45. Oda Y, Mizutani K, Hase I, Nakamoto T, Hamaoka N, Asada A. Fentanyl inhibits metabolism of midazolam: Competitive inhibition of CYP3A4 in vitro. Br J Anaesth 1999; 82: 900-903
46. Nims RW, Prough RA, Jones CR, Stockus DL, Dragnev KH, Thomas PE, Lubet RA. In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam. Drug Metab Dispos 1997; 25: 750-756
47. Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 1997; 117: 13-23
48. Ourlin JC, Handschin C, Kaufmann M, Meyer UA. A link between cholesterol levels and phenobarbital induction of cytochromes P450. Biochem Biophys Res Commun 2002; 291: 378-384
49. Staudinger J, Liu Y, Madan A, Habeebu S, Klaassen CD. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 2001; 29: 1467-1472
50. Hung DY, Chang P, Cheung K, McWhinney B, Masci PP, Weiss M, Roberts MC. Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug. J Pharmacol Exp Ther 2002; 301: 1079-1087
51. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65: 166-176